Use of pegylated interferon in hypereosinophilic syndrome

Joseph H. Butterfield, Catherine R. Weiler

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients. PEG-IFN alpha-2a was substituted when PEG-IFN alpha-2b became unavailable. PEG-IFNs were well tolerated and controlled eosinophilia. The dose of PEG-IFNs often could be tapered and the interval between doses lengthened beyond 7. days. Adverse effects included dose-related increases in liver enzyme levels, hair loss, mild lymphopenia, and neutropenia. PEG-IFNs are effective treatment of HES.

Original languageEnglish (US)
Pages (from-to)192-197
Number of pages6
JournalLeukemia Research
Issue number2
StatePublished - Feb 2012


  • Eosinophilia
  • Hypereosinophilic syndrome
  • Immunoglobulins
  • Interferon
  • Methoxy polyethylene glycol

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Use of pegylated interferon in hypereosinophilic syndrome'. Together they form a unique fingerprint.

Cite this